13.15 | 10.15 Utility of Blood-Based Proteomic Profiling for Early & Late Stage Lung Cancer Treatment

Time: 1:15 pm
day: Day One


  • Importance of interpreting the host-immune response from blood using mass spectrometry coupled with AI
  • Utility of blood-based proteomic biomarkers for both early stage and late stage lung cancer treatment decisions
  • Application of proteomic analyses in biomarker research, clinical trial enrollment and real world diagnostic testing